

Maximilian F Konig

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/21824/maximilian-f-konig-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52
papers

1,157
citations

16
h-index

33
g-index

60
ext. papers

1,705
ext. citations

10.4
avg, IF

5.01
L-index

#	Paper	IF	Citations
52	The impact of COVID-19 on rheumatology training-results from the COVID-19 Global Rheumatology Alliance trainee survey.. <i>Rheumatology Advances in Practice</i> , 2022 , 6, rkac001	1.1	0
51	Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients.. <i>Frontiers in Medicine</i> , 2022 , 9, 849222	4.9	
50	More on CD19-CAR T Cells in Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2021 , 385, e67	59.2	0
49	SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Disease: A Systematic Literature Review And Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	20
48	The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality from COVID-19 2021 ,		3
47	Bispecific antibodies targeting mutant neoantigens. <i>Science Immunology</i> , 2021 , 6,	28	42
46	Author response: Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection 2021 ,		2
45	Targeting loss of heterozygosity for cancer-specific immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	14
44	TCR α -chain-directed bispecific antibodies for the treatment of T cell cancers. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	10
43	The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19. <i>Frontiers in Medicine</i> , 2021 , 8, 637647	4.9	12
42	Targeting a neoantigen derived from a common mutation. <i>Science</i> , 2021 , 371,	33.3	68
41	Inside and Out. <i>New England Journal of Medicine</i> , 2021 , 384, 1753-1760	59.2	
40	Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2021 , 73, 997-1004	9.5	7
39	Targeting public neoantigens for cancer immunotherapy. <i>Nature Cancer</i> , 2021 , 2, 487-497	15.4	10
38	Inflammatory arthritis in patients with COVID-19. <i>Translational Research</i> , 2021 , 232, 49-59	11	3
37	Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection. <i>ELife</i> , 2021 , 10,	8.9	7
36	Ten Rules for Conducting Retrospective Pharmacoepidemiological Analyses: Example COVID-19 Study. <i>Frontiers in Pharmacology</i> , 2021 , 12, 700776	5.6	0

35	Associations of Antibodies Targeting Periodontal Pathogens With Subclinical Coronary, Carotid, and Peripheral Arterial Atherosclerosis in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 568-575	9.5	3
34	Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. <i>Nature Communications</i> , 2021 , 12, 5271	17.4	5
33	Citrullination of a phage-displayed human peptidome library reveals the fine specificities of rheumatoid arthritis-associated autoantibodies. <i>EBioMedicine</i> , 2021 , 71, 103506	8.8	3
32	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology</i> , 2021 , 3, e707-e714	14.2	11
31	Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. <i>Expert Review of Clinical Immunology</i> , 2020 , 16, 1185-1204	5.1	18
30	Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1386-1388	2.4	56
29	Digit Ulcerations in a Young Woman. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 385-386	3.6	3
28	Exposure to before Symptom Onset and the Risk of Evolving to Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
27	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <i>Expert Review of Clinical Immunology</i> , 2020 , 16, 659-666	5.1	40
26	The microbiome in autoimmune rheumatic disease. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020 , 34, 101473	5.3	29
25	Acute Bilateral Pseudogout of the Temporomandibular Joint. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1159-1161	9.5	3
24	Preventing cytokine storm syndrome in COVID-19 using β_1 adrenergic receptor antagonists. <i>Journal of Clinical Investigation</i> , 2020 , 130, 3345-3347	15.9	69
23	Response to: Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis by Singer. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	
22	A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic. <i>ACR Open Rheumatology</i> , 2020 , 2, 491-495	3.5	3
21	Response to: Correspondence on Hydroxychloroquine, COVID-19 and the role of the rheumatologist by Graef by Lo. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	1
20	: hydroxychloroquine, COVID-19 and the role of the rheumatologist. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 734-736	2.4	32
19	Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine	2.4	4
18	Response to comment on "H-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis". <i>Science Translational Medicine</i> , 2018 , 10,	17.5	7

17	Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018 , 20, 59	5.7	11
16	Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 141-148	2.4	10
15	Rheumatoid Arthritis-Associated Autoimmunity Due to and Its Resolution With Antibiotic Therapy. <i>Frontiers in Immunology</i> , 2018 , 9, 2352	8.4	24
14	Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2018 , 9, 2696	8.4	22
13	Sarcoidosis and autoimmune diseases: differences, similarities and overlaps. <i>Current Opinion in Pulmonary Medicine</i> , 2018 , 24, 504-512	3	22
12	Antibodies to native and citrullinated RA33 (hnRNP A2/B1) challenge citrullination as the inciting principle underlying loss of tolerance in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 2022-2028	2.4	36
11	Elevated Erythrocyte Sedimentation Rate Is Predictive of Interstitial Lung Disease and Mortality in Dermatomyositis: a Korean Retrospective Cohort Study. <i>Journal of Korean Medical Science</i> , 2016 , 31, 389-96	4.7	12
10	A Critical Reappraisal of Neutrophil Extracellular Traps and NETosis Mimics Based on Differential Requirements for Protein Citrullination. <i>Frontiers in Immunology</i> , 2016 , 7, 461	8.4	146
9	Respiratory Distress and Nephropathy in a Young Male With Small-Joint Polyarthritis. <i>Arthritis Care and Research</i> , 2016 , 68, 1173-9	4.7	
8	Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. <i>Science Translational Medicine</i> , 2016 , 8, 369ra176	17.5	289
7	PPAD is not targeted as a citrullinated protein in rheumatoid arthritis, but remains a candidate for inducing autoimmunity. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e8	2.4	8
6	Defining the role of Porphyromonas gingivalis peptidylarginine deiminase (PPAD) in rheumatoid arthritis through the study of PPAD biology. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 2054-61	2.4	73
5	Subscapular bursitis as a rare manifestation of dermatomyositis: a case report. <i>European Journal of Rheumatology</i> , 2015 , 2, 80-82	1.7	1
4	FRI0356 Antibodies to Perforin-Induced Citrullinated Hnrnp A1 Are Associated with Erosive Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 516.1-516	2.4	
3	Insights into the significance of peptidylarginine deiminase 4 and antibodies against citrullinated antigens in the absence of "true ACPAs" in an experimental model of arthritis: comment on the article by Shelef et al. <i>Arthritis and Rheumatology</i> , 2014 , 66, 2642-4	9.5	6
2	Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome		10
1	COVID-19 outcomes among hospitalized men with or without exposure to alpha-1-adrenergic receptor blocking agents		1